157 related articles for article (PubMed ID: 28106255)
1. Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.
Mesguich C; Cazeau AL; Bouabdallah K; Hindié E
Br J Haematol; 2018 Apr; 181(1):124-125. PubMed ID: 28106255
[No Abstract] [Full Text] [Related]
2. Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".
Hindié E; Mesguich C; Bouabdallah K; Milpied N
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1937-1939. PubMed ID: 28707119
[No Abstract] [Full Text] [Related]
3. Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee.
Dann EJ; Paltiel O
Br J Haematol; 2018 Oct; 183(1):131-133. PubMed ID: 28832981
[No Abstract] [Full Text] [Related]
4. Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?
Adams HJA; Kwee TC
Br J Haematol; 2018 Apr; 181(1):122-123. PubMed ID: 28025838
[No Abstract] [Full Text] [Related]
5. Value of detecting bone marrow involvement in Hodgkin lymphoma - Response to Adams and Kwee.
Pedersen MA; Gormsen LC; d'Amore F
Br J Haematol; 2019 Nov; 187(3):396-397. PubMed ID: 31483478
[No Abstract] [Full Text] [Related]
6. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. In Reply to Adams and Kwee.
Simontacchi G; Filippi AR; Ciammella P; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):725-6. PubMed ID: 26461018
[No Abstract] [Full Text] [Related]
7. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
8. Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma.
Adams HJA; Kwee TC
Br J Haematol; 2018 Oct; 183(1):129-131. PubMed ID: 28905368
[No Abstract] [Full Text] [Related]
9. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
[TBL] [Abstract][Full Text] [Related]
10. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
11. Overestimated value of FDG-PET based bone marrow evaluation in lymphoma: Response to Adams and Kwee.
Ujjani CS; Cheson BD
Br J Haematol; 2017 Oct; 179(2):337-339. PubMed ID: 27391783
[No Abstract] [Full Text] [Related]
12. Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma.
Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji JB
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):344-345. PubMed ID: 27796542
[No Abstract] [Full Text] [Related]
13. Interim FDG-PET/CT in Hodgkin lymphoma: what are we actually looking at?
Adams HJA; Kwee TC
Acta Oncol; 2018 Aug; 57(8):1128-1130. PubMed ID: 29463178
[No Abstract] [Full Text] [Related]
14. Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin Lymphoma.
Adams HJA; Kwee TC;
J Natl Compr Canc Netw; 2018 Mar; 16(3):226-228. PubMed ID: 29523660
[No Abstract] [Full Text] [Related]
15. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
16. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
17. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
Adams HJ; Kwee TC
Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
[TBL] [Abstract][Full Text] [Related]
18. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis.
Adams HJA; Kwee TC
Eur J Radiol; 2016 Nov; 85(11):1963-1970. PubMed ID: 27776647
[TBL] [Abstract][Full Text] [Related]
19. Measurement uncertainty and clinical impact of target-to-background ratios derived by interim FDG-PET/CT in Hodgkin lymphoma: reply to Laffon and Martan.
Annunziata S; Calcagni ML; Indovina L; Rufini V
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2140-2141. PubMed ID: 28879394
[No Abstract] [Full Text] [Related]
20. Interim FDG-PET in lymphoma, a questionable practice in hematology.
Adams HJA; Kwee TC
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2014-2017. PubMed ID: 28761975
[No Abstract] [Full Text] [Related]
[Next] [New Search]
